fluorouracil

5-FU has been found to be an agent that may cause direct reversible cardiac toxicity or exacerbate the cause of myocardial dysfunction.

6 It was found that when used alone, 5-FU did not perform better than steroid.

After demonstrating that the combined treatment reduces AKs in mice, they conducted the study of 131 patients with AKs, randomized to treatment with a cream containing 5% 5-FU and 0.

On the scalp, combination therapy reduced the number of AKs by 76%, while 5-FU alone reduced the number by only 6%.

History of hypersensitivity and/or intolerance to 5-FU.

The repaired tendons in this group were not topically treated with 5-FU *Research subgroup 2a: This group included the same 16 rabbits of subgroup 1a, but in the third digit of right hind paw, the FDP was partially divided and repaired with modified Kessler 2 core 5/0 Ethibond sutures (Johnson and Johnson, Somerville, NJ, USA) and a 6-0 Prolene (Johnson and Johnson) stitch for the circumferential epitenon repair.

5-FU injection (250 mg/10 ml) was purchased from Xudong-haipu parmaceutical company, Shanghai, China; regents for western blot and RT-PCR were purchased from Bio-Rad, USA; P53, bcl-2, bax, bid and [beta]-actin antibodies, secondary antibodies were obtained from cell signaling, MA, USA.

The inclusion criteria related to adult Pakistani patients with a definitive diagnosis of cancer and having received 5-FU and 5-FU based chemotherapy regimens during January 2002 and December 2004.

Cases of mild precordial pain with ST segment and/or T-wave changes, myocardial infarction, left ventricular failure, cardiogenic shock, ventricular and supraventricular arrhythmias, and sudden cardiac death have been reported (2-6) in >20% of patients receiving 5-FU.

Adjuvant chemotherapy including combination regimens of 5-FU is beneficial after surgery for premenopausal women with stage I (node-negative) breast cancer and for postmenopausal women with stage I (node-negative) breast cancer adjuvant tamoxifen is beneficial either alone for 5 years or in combination with chemotherapy.

The 42% response rate achieved with the administration of TEGAFIRI and the 39% response rate in patients receiving TEGAFOX are promising and comparable to those results achieved with infused 5-FU combinations.

We are enthusiastic about CoFactor's potential to enhance the efficacy and safety of 5-FU chemotherapy in the treatment of refractory breast cancer.

50] para 5-FU fueron: 3,57 (r=-0,96 p<0,005), 15,95 (r=-0,97 p<0,025) y 0,51 (r=-0,88 p=0,01) para colo-205, K562 y 3T3, respectivamente.

In the adjuvant setting, patients with stage III colon cancer (tumor-node-metastasis T1-3, N1-2 [any lymph node involvement], M0) should receive oxaliplatin with 5-fluorouracil (5-FU) and leucovorin (the FOLFOX regimen); or capecitabine (Xeloda); or 5-FU and leucovorin without oxaliplatin, Paul Engstrom, M.

However, as a single-agent, 5-FU was found to be only modestly beneficial, with response rates rarely exceeding 15%.